论文部分内容阅读
目的:探讨抑癌基因p16、细胞周期蛋白cyclin D1和凋亡抑制基因survivin在膀胱移行细胞癌中的表达及意义。方法:膀胱移行细胞癌组67例,10例正常正常膀胱粘膜作为对照,采用免疫组织化学方法检测p16和cyclin D1、survivin蛋白表达,然后分析上述三种蛋白在膀胱癌组织中的表达情况,以及随着不同临床分期和病理分级表达的变化。结果:所有膀胱癌患者平均年龄58.16岁,其中男性患者38例。免疫组织化学分析表明,p16和cyclin D1、survivin蛋白均表达在细胞的细胞核。膀胱癌组织中P16表达明显低于正常对照组,而cyclin D1和survivin表达明显高于正常对照组。随着临床分期的进展,p16表达明显下降,cyclinD1表达明显上升;而随着膀胱癌病理分级升高,p16表达明显下降,survivin表达上升。此外,膀胱癌组织中,p16与cyclin D1p16之间存在着明确的负相关。结论:p16、cyclin D1、survivin在膀胱移行细胞癌的生物学行为中起重要作用,p16,cyclin D1和survivin与膀胱移行细胞癌的恶性进展有关。
Objective: To investigate the expression and significance of tumor suppressor gene p16, cyclin D1 and apoptosis inhibitor survivin in bladder transitional cell carcinoma. Methods: Sixty-seven cases of bladder transitional cell carcinoma and 10 cases of normal bladder mucosa were used as control. The expression of p16, cyclin D1 and survivin protein was detected by immunohistochemistry. The expression of the above three proteins in bladder cancer was analyzed. With different clinical stage and histological grade changes. Results: The average age of all bladder cancer patients was 58.16 years, including 38 males. Immunohistochemical analysis showed that p16 and cyclin D1, survivin protein were expressed in the cell nucleus. The expression of P16 in bladder cancer was significantly lower than that in normal control group, while the expression of cyclin D1 and survivin in bladder cancer was significantly higher than that in normal control group. With the progress of clinical stage, the expression of p16 decreased significantly and the expression of cyclinD1 increased significantly. However, the expression of p16 decreased and the expression of survivin increased as the pathological grade of bladder cancer increased. In addition, there is a clear negative correlation between p16 and cyclin D1p16 in bladder cancer. Conclusions: p16, cyclin D1 and survivin play an important role in the biological behavior of transitional cell carcinoma of the bladder. The expressions of p16, cyclin D1 and survivin are associated with the malignant progression of bladder transitional cell carcinoma.